Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study.
Yuksel UrunHatime Arzu YasarHande TurnaEce EsinA Murat SedefAli AlkanBerna OksuzogluNuriye OzdemirMa Nahit SendurAhmet SezerSaadettin KılıckapGungor UtkanTulay AkmanHakan AkbulutIsmail CelikHuseyin AbalıPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2018)
Ipilimumab improved survival of patients with metastatic malign melanoma. However, patients with fewer metastatic sites and higher absolute lymphocytes count have a significantly better benefit. To determine if these markers could be used to direct patient therapy, further validation analysis is needed.